Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
New, improved formulation set to replace EGRIFTA SV®MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or ...
Theratechnologies Shares Rise on FDA Approval for HIV-Induced Stomach Fat Treatment
Shares of Theratechnologies jumped after the company received Food and Drug Administration approval for Egrifta WR, its treatment for excess abdominal fat in adults with HIV and lipodystrophy.